Suominen P, Punnonen K, Rajamäki A, Irjala K
Department of Clinical Chemistry, University Hospital of Turku, Finland.
Clin Chem. 1997 Sep;43(9):1641-6.
During the last few years the measurement of serum-soluble transferrin receptor (sTfR) has been introduced as a tool to detect iron deficiency and as an analyte to differentiate between anemia caused by iron deficiency (IDA) and that caused by chronic disease (ACD). Commercially available methods have emerged to make diagnostics by sTfR more readily accessible. We documented the analytical performance of a newly introduced IDeA sTfR immunoenzymometric assay (IEMA) by Orion Diagnostica. We also evaluated its clinical performance in 98 consecutive anemic patients, with information derived from bone marrow aspirate samples as the reference for iron status. The clinical usefulness of two other commercially available sTfR assays was assessed for comparison. The analytical performance and clinical applicability of the IDeA were sufficient to support reliable clinical work. We conclude that IDA and iron deficiency in the presence of inflammatory states can be differentiated efficiently from ACD with this new commercial test to measure sTfR.
在过去几年中，血清可溶性转铁蛋白受体（sTfR）的检测已被用作检测缺铁的工具，以及区分缺铁性贫血（IDA）和慢性病贫血（ACD）的分析物。市面上已出现了一些方法，使通过sTfR进行诊断变得更容易。我们记录了Orion Diagnostica公司新推出的IDeA sTfR免疫酶分析法（IEMA）的分析性能。我们还评估了其在98例连续贫血患者中的临床性能，并以骨髓穿刺样本所提供的信息作为铁状态的参考。为作比较，我们评估了另外两种市售sTfR检测方法的临床实用性。IDeA的分析性能和临床适用性足以支持可靠的临床工作。我们得出结论，通过这种新的市售检测方法测量sTfR，可以有效地将IDA以及炎症状态下的缺铁与ACD区分开来。
